Willem W. Overwijk, Ph.D. - Publications

Affiliations: 
2001 The George Washington University, Washington, DC, United States 
Area:
Immunology, Oncology, Biochemistry

66 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Ma Q, Zhou D, DeLyria ES, Wen X, Lu W, Thapa P, Liu C, Li D, Bassett RL, Overwijk WW, Hwu P, Li C. Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 27681378 DOI: 10.1097/CJI.0000000000000145  0.68
2016 Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, Petaccia De Macedo M, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, ... ... Overwijk WW, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. PMID 27301722 DOI: 10.1158/2159-8290.CD-15-1545  0.68
2015 Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, ... ... Overwijk WW, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. PMID 26645196 DOI: 10.1158/2159-8290.CD-15-0283  0.68
2015 Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, ... ... Overwijk WW, et al. Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology. 4: e998538. PMID 26137416 DOI: 10.1080/2162402X.2014.998538  0.68
2015 Singh M, Overwijk WW. Intratumoral immunotherapy for melanoma. Cancer Immunology, Immunotherapy : Cii. PMID 26050024 DOI: 10.1007/s00262-015-1727-z  0.68
2015 Anthony SM, Howard ME, Hailemichael Y, Overwijk WW, Schluns KS. Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways. Plos One. 10: e0120274. PMID 25756182 DOI: 10.1371/journal.pone.0120274  0.68
2014 Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. Journal of Immunology (Baltimore, Md. : 1950). 193: 4722-31. PMID 25252955 DOI: 10.4049/jimmunol.1401160  0.68
2014 Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Translational Oncology. 7: 484-92. PMID 24969538 DOI: 10.1016/j.tranon.2014.05.008  0.68
2014 Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature Medicine. 20: 676-81. PMID 24859530 DOI: 10.1038/nm.3560  0.68
2014 Hailemichael Y, Overwijk WW. Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. The International Journal of Biochemistry & Cell Biology. 53: 46-50. PMID 24796845 DOI: 10.1016/j.biocel.2014.04.019  0.68
2014 Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, ... ... Overwijk WW, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications. 5: 3459. PMID 24619206 DOI: 10.1038/ncomms4459  0.68
2013 Overwijk WW, Wang E, Marincola FM, Rammensee HG, Restifo NP. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. Journal For Immunotherapy of Cancer. 1: 11. PMID 24829748 DOI: 10.1186/2051-1426-1-11  0.68
2013 Hailemichael Y, Overwijk WW. Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. Oncoimmunology. 2: e24743. PMID 24073366 DOI: 10.4161/onci.24743  0.68
2013 Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, et al. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 276-86. PMID 23603862 DOI: 10.1097/CJI.0b013e31829419f3  0.68
2013 Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, ... ... Overwijk WW, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion Nature Medicine. 19: 465-472. PMID 23455713 DOI: 10.1038/nm.3105  0.68
2013 Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1225-31. PMID 23307859 DOI: 10.1158/1078-0432.CCR-12-1630  0.68
2013 Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, ... ... Overwijk WW, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 393-403. PMID 23204132 DOI: 10.1158/1078-0432.CCR-12-1626  0.68
2013 Chakravarti N, Peddareddigari VG, Warneke CL, Johnson MM, Overwijk WW, Hwu P, Prieto VG. Differential expression of the G-protein-coupled formyl Peptide receptor in melanoma associates with aggressive phenotype. The American Journal of Dermatopathology. 35: 184-90. PMID 23147350 DOI: 10.1097/DAD.0b013e31825b2506  0.68
2013 Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annual Review of Medicine. 64: 71-90. PMID 23092383 DOI: 10.1146/annurev-med-112311-083918  0.68
2012 Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 120: 4533-43. PMID 22936666 DOI: 10.1182/blood-2012-02-407163  0.68
2012 Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Research. 72: 5209-18. PMID 22915761 DOI: 10.1158/0008-5472.CAN-12-1187  0.68
2012 Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, Cannan D, Ramacher M, Kato M, Overwijk WW, Chen SH, Umansky VY, Sikora AG. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. Journal of Immunology (Baltimore, Md. : 1950). 188: 5365-76. PMID 22529296 DOI: 10.4049/jimmunol.1103553  0.68
2012 Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizée G, Zhou D, Overwijk WW, Hwu P. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 276-82. PMID 22421945 DOI: 10.1097/CJI.0b013e31824e7f43  0.68
2012 Sikora AG, Hailemichael Y, Overwijk WW. Conference scene: immune effector mechanisms in tumor immunity. Immunotherapy. 4: 141-3. PMID 22339456 DOI: 10.2217/imt.11.177  0.68
2011 Li HS, Gelbard A, Martinez GJ, Esashi E, Zhang H, Nguyen-Jackson H, Liu YJ, Overwijk WW, Watowich SS. Cell-intrinsic role for IFN-α-STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response. Blood. 118: 3879-89. PMID 21828128 DOI: 10.1182/blood-2011-04-349761  0.68
2011 Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4882-91. PMID 21632855 DOI: 10.1158/1078-0432.CCR-10-2769  0.68
2011 Lou Y, Liu C, Lizée G, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D, Overwijk WW, Hwu P. Antitumor activity mediated by CpG: the route of administration is critical. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 279-88. PMID 21389870 DOI: 10.1097/CJI.0b013e31820d2a05  0.68
2011 Park HJ, Qin H, Cha SC, Sharma R, Chung Y, Schluns KS, Neelapu SS, Overwijk WW, Hwu P, Kwak LW. Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines Vaccine. 29: 3476-3482. PMID 21382485 DOI: 10.1016/j.vaccine.2011.02.061  0.68
2010 Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizée G, Hwu P. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5458-68. PMID 20889916 DOI: 10.1158/1078-0432.CCR-10-0712  0.68
2010 Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2550-61. PMID 20388845 DOI: 10.1158/1078-0432.CCR-10-0279  0.68
2010 Frasca L, Stonier SW, Overwijk WW, Schluns KS. Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types. Journal of Leukocyte Biology. 88: 69-78. PMID 20354106 DOI: 10.1189/jlb.1209816  0.68
2010 Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1834-44. PMID 20215556 DOI: 10.1158/1078-0432.CCR-09-3123  0.68
2009 Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 31: 787-98. PMID 19879162 DOI: 10.1016/j.immuni.2009.09.014  0.68
2009 Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. Journal of Immunology (Baltimore, Md. : 1950). 182: 7398-407. PMID 19494262 DOI: 10.4049/jimmunol.0802982  0.68
2009 Overwijk WW, Schluns KS. Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clinical Immunology (Orlando, Fla.). 132: 153-65. PMID 19428306 DOI: 10.1016/j.clim.2009.03.512  0.68
2009 Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P, Chang DZ, Courtney A, Sastry JK, Wang PG, Li C, Zhou D. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 27: 3484-8. PMID 19200815 DOI: 10.1016/j.vaccine.2009.01.047  0.68
2008 Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, Cooper LJ, Gelovani J, Hwu P. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proceedings of the National Academy of Sciences of the United States of America. 105: 14342-6. PMID 18794521 DOI: 10.1073/pnas.0804105105  0.68
2008 Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. The Journal of Clinical Investigation. 118: 1165-75. PMID 18259609 DOI: 10.1172/JCI33583  0.68
2007 Liu S, Lizée G, Lou Y, Liu C, Overwijk WW, Wang G, Hwu P. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. International Immunology. 19: 1213-21. PMID 17898044 DOI: 10.1093/intimm/dxm093  0.68
2006 Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4794-803. PMID 16914564 DOI: 10.1158/1078-0432.CCR-06-0944  0.68
2006 Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. Journal of Immunology (Baltimore, Md. : 1950). 176: 5213-22. PMID 16621986  0.68
2006 Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2359s-2365s. PMID 16609059 DOI: 10.1158/1078-0432.CCR-05-2537  0.68
2005 Overwijk WW. Breaking tolerance in cancer immunotherapy: time to ACT. Current Opinion in Immunology. 17: 187-94. PMID 15766680 DOI: 10.1016/j.coi.2005.01.011  0.68
2005 Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. Journal of Immunology (Baltimore, Md. : 1950). 174: 2591-601. PMID 15728465  0.68
2003 Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. The Journal of Experimental Medicine. 198: 569-80. PMID 12925674 DOI: 10.1084/jem.20030590  0.68
2002 Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. The Prostate. 53: 183-91. PMID 12386918 DOI: 10.1002/pros.10136  0.68
2001 Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. Unit 20.1. PMID 18432774 DOI: 10.1002/0471142735.im2001s39  0.68
2001 Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P. Immunization against endogenous retroviral tumor-associated antigens. Cancer Research. 61: 7920-4. PMID 11691813  0.68
2001 van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. The Journal of Experimental Medicine. 194: 481-9. PMID 11514604 DOI: 10.1084/jem.194.4.481  0.68
2001 Zoeteweij JP, Moses AV, Rinderknecht AS, Davis DA, Overwijk WW, Yarchoan R, Orenstein JM, Blauvelt A. Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus Blood. 97: 2374-2380. PMID 11290600 DOI: 10.1182/blood.V97.8.2374  0.68
2001 Overwijk WW, Restifo NP. Creating therapeutic cancer vaccines: notes from the battlefield. Trends in Immunology. 22: 5-7. PMID 11286676 DOI: 10.1016/S1471-4906(00)01793-2  0.68
2000 Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Critical Reviews in Immunology. 20: 433-50. PMID 11396680  0.68
2000 Lee K, Overwijk WW, O'Toole M, Swiniarski H, Restifo NP, Dorner AJ, Wolf SF, Sturmhoefel K. Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 20: 589-96. PMID 10888115 DOI: 10.1089/10799900050044787  0.68
2000 Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA. An autologous oral DNA vaccine protects against murine melanoma. Proceedings of the National Academy of Sciences of the United States of America. 97: 5492-7. PMID 10779556 DOI: 10.1073/pnas.090097697  0.68
2000 Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. The Journal of Experimental Medicine. 191: 1221-32. PMID 10748239 DOI: 10.1084/jem.191.7.1221  0.68
2000 Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anticancer vaccines. The Cancer Journal From Scientific American. 6: S76-80. PMID 10685664  0.68
2000 Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Research. 60: 253-8. PMID 10667570  0.68
2000 Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. Journal of Immunology (Baltimore, Md. : 1950). 164: 562-5. PMID 10623795  0.68
1999 Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 96: 2982-7. PMID 10077623 DOI: 10.1073/pnas.96.6.2982  0.68
1998 Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. Journal of the National Cancer Institute. 90: 1881-7. PMID 9862625  0.68
1998 Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. Journal of Immunology (Baltimore, Md. : 1950). 161: 5313-20. PMID 9820504  0.68
1998 Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. The Journal of Experimental Medicine. 188: 277-86. PMID 9670040 DOI: 10.1084/jem.188.2.277  0.68
1997 Overwijk WW, Surman DR, Tsung K, Restifo NP. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods (San Diego, Calif.). 12: 117-23. PMID 9184376 DOI: 10.1006/meth.1997.0461  0.68
1997 Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 15: 387-94. PMID 9141209 DOI: 10.1016/S0264-410X(96)00195-8  0.68
1997 Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. Journal of Immunotherapy (Hagerstown, Md. : 1997). 20: 15-25. PMID 9101410 DOI: 10.1097/00002371-199701000-00002  0.68
1997 Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proceedings of the National Academy of Sciences of the United States of America. 94: 3183-8. PMID 9096367 DOI: 10.1073/pnas.94.7.3183  0.68
Show low-probability matches.